Active Biotech AB (publ) (ACTI.ST)

SEK 0.11

(-7.32%)

Market Cap (In SEK)

123.71 Million

Revenue (In SEK)

-

Net Income (In SEK)

-45.8 Million

Avg. Volume

429.4 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.105-1.478
PE
-
EPS
-
Beta Value
0.475
ISIN
SE0001137985
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Helen Tuvesson Ph.D.
Employee Count
-
Website
https://www.activebiotech.com
Ipo Date
2003-12-19
Details
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.